Výsledky vyhledávání - "J. F. Schved"

Akademický článek

Post-viral idiopathic purpura fulminans is associated with inherited thrombophilia and anti-cardiolipin antibodies

Autor: A. Theron, S. Ayadi, E. Boissier, O. Dautremay, J.-F. Schved, N. Sirvent, I. Diaz, G. Captier, C. Biron-Andreani, E. Jeziorski

Publikováno v: Frontiers in Pediatrics, Vol 11 (2023)

IntroductionIdiopathic purpura fulminans (IPF) is a rare and severe coagulation disorder, associated with transient anti-protein S (anti-PS) antibodies in the context of post-viral infection such as varicella. Anti-protein S antibodies are frequently

Externí odkaz: https://doaj.org/article/cbb0945dbbd645088b693c2364a9a8e3

Zobrazit plný text záznamu

Pain relief with Eptacog beta in haemophilia patients with inhibitors

Autor: U Nowak-Göttl, C Hermans, J Mahlangu, S Ahuja, M Carcao, G Castaman, J Davis, O Khan, W Miesbach, M Reding, J-F Schved, L Villareal Martinez, M Wang, J Windyga, M Witkop, G Young, D Bonzo, I Mitchell, C Kessler

Publikováno v: GTH Congress 2023 – 67th Annual Meeting of the Society of Thrombosis and Haemostasis Research – The patient as a benchmark.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a4b8bd521930167a797d3bd02c7af1d
https://doi.org/10.1055/s-0042-1760510

Zobrazit plný text záznamu

The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors

Publikováno v: HAEMOPHILIA
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Haemophilia, Vol. 27, no. 6, p. 921-931 (2021)

Introduction Haemophilia patients with inhibitors often require a bypassing agent (BPA) for bleeding episode management. Eptacog beta (EB) is a new FDA-approved recombinant activated human factor VII BPA for the treatment and control of bleeding in h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::460af57ed40fc47782a37557cb179f76
https://doi.org/10.1111/hae.14419

Zobrazit plný text záznamu

Plný text ve formátu HTML

PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors

Publikováno v: Haemophilia, Vol. 27, no. 6, p. 911-920 (2021)

Introduction Surgical procedures in persons with haemophilia A or B with inhibitors (PwHABI) require the use of bypassing agents (BPA) and carry a high risk of complications. Historically, only two BPAs have been available; these are reported to have

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d948d39016ac2aa490b5d6ad9552ede8
https://doi.org/10.1111/hae.14418

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Antivitaminiques K, anticoagulants oraux directs : où est la vérité ?

Autor: J.-F. Schved, J.-P. Laroche

Publikováno v: Journal des Maladies Vasculaires. 41:383-388

Vitamin K antagonists (VKA) and direct oral anticoagulants (DOACs) are now in competition. The companies are trying to replace VKA by DOACs, totally or at least greatly VKA should VKA disappear in favor of DOACs? There are still many questions about

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d60983bb690a0ff7e5eda3e0fedc0748
https://doi.org/10.1016/j.jmv.2016.10.002

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

European retrospective study of real-life haemophilia treatment

Autor: Alberto Tosetto, Elena Santagostino, Mt. Álvarez-Román, U. Scholz, Stefan Lethagen, Giancarlo Castaman, Christopher A. Ludlam, C. R. M. Hay, Johannes Oldenburg, Gerry Dolan, R. Parra Lopez, Marc Trossaert, Cédric Hermans, Margareta Holmström, Silvia Linari, J.-F. Schved, T. Albert, A. Boban, Erik Berntorp

Publikováno v: Haemophilia. 23:105-114

Introduction: Haemophilia treatment varies significantly between individuals, countries and regions and details of bleed rates, factor consumption and injection frequency are often not available. Aim: To provide an overview of the FVIII/FIX treatment

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3654e2574e28750cfcce75795111c94
https://doi.org/10.1111/hae.13111

Zobrazit plný text záznamu

[Direct oral anticoagulants (DOACS): A necessary focus]

Autor: J P, Laroche, F, Becker, J F, Schved

Publikováno v: Journal de medecine vasculaire. 43(3)

In 2008, we decided to enter the era of direct oral anticoagulants (DOACS). Was that the right decision to make? The answer will depend on how well we meet the conditions of proper use. This means avoiding underdosing and overdosing as well as unders

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ec27bf085b10cf6121af5e79f2f403da
https://pubmed.ncbi.nlm.nih.gov/29754730

Zobrazit plný text záznamu

Maladies hémorragiques congénitales : quel avenir pour les dérivés plasmatiques par rapport aux recombinants et aux produits sanguins labiles ?

Autor: J.-F. Schved

Publikováno v: Transfusion Clinique et Biologique. 22:85-89

Until 1990, congenital hemorrhagic disorders were treated by plasma-derived concentrates. The first recombinant drug, recombinant factor VIII was available after this date and few years later recombinant factor IX could also be proposed to patients.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a8dec84ed3260edd81aa41971675356
https://doi.org/10.1016/j.tracli.2015.03.006

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání